Biogen leaps into a showdown between Roche and Regeneron, betting on a potential new franchise player
Plagued by a woeful launch for its Alzheimer’s franchise, Biogen is betting $30 million on some reliable partners at Genentech to come up with a fast new franchise drug — outside of its CNS specialty.
The therapy is mosunetuzumab, a “breakthrough” designate at the FDA which looks perfectly positioned for a shot at an accelerated approval. Working on their longtime collaboration on CD20, Biogen will chip in on some of last year’s R&D work and add a $30 million payment to step in to co-commercialize the drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.